vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and Westrock Coffee Co (WEST). Click either name above to swap in a different company.
Westrock Coffee Co is the larger business by last-quarter revenue ($339.5M vs $196.9M, roughly 1.7× Pacira BioSciences, Inc.). On growth, Westrock Coffee Co posted the faster year-over-year revenue change (48.3% vs 5.1%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $27.8M). Over the past eight quarters, Westrock Coffee Co's revenue compounded faster (32.8% CAGR vs 8.5%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Westrock Coffee Co is a global integrated coffee, tea and functional beverage solutions provider. It sources, roasts, manufactures and distributes coffee products, ready-to-drink beverages and custom formulations for retail, foodservice and commercial clients across North America and other key markets.
PCRX vs WEST — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.9M | $339.5M |
| Net Profit | — | $-22.6M |
| Gross Margin | 79.5% | 11.5% |
| Operating Margin | 1.2% | -2.6% |
| Net Margin | — | -6.6% |
| Revenue YoY | 5.1% | 48.3% |
| Net Profit YoY | — | 8.3% |
| EPS (diluted) | $0.05 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.9M | $339.5M | ||
| Q3 25 | $179.5M | $354.8M | ||
| Q2 25 | $181.1M | $280.9M | ||
| Q1 25 | $168.9M | $213.8M | ||
| Q4 24 | $187.3M | $229.0M | ||
| Q3 24 | $168.6M | $220.9M | ||
| Q2 24 | $178.0M | $208.4M | ||
| Q1 24 | $167.1M | $192.5M |
| Q4 25 | — | $-22.6M | ||
| Q3 25 | $5.4M | $-19.1M | ||
| Q2 25 | $-4.8M | $-21.6M | ||
| Q1 25 | $4.8M | $-27.2M | ||
| Q4 24 | — | $-24.6M | ||
| Q3 24 | $-143.5M | $-14.3M | ||
| Q2 24 | $18.9M | $-17.8M | ||
| Q1 24 | $9.0M | $-23.7M |
| Q4 25 | 79.5% | 11.5% | ||
| Q3 25 | 80.9% | 11.7% | ||
| Q2 25 | 77.4% | 14.7% | ||
| Q1 25 | 79.7% | 13.6% | ||
| Q4 24 | 78.7% | 16.6% | ||
| Q3 24 | 76.9% | 16.8% | ||
| Q2 24 | 75.1% | 19.9% | ||
| Q1 24 | 71.6% | 19.4% |
| Q4 25 | 1.2% | -2.6% | ||
| Q3 25 | 3.5% | -2.4% | ||
| Q2 25 | 4.7% | -5.3% | ||
| Q1 25 | 1.2% | -6.1% | ||
| Q4 24 | 13.2% | -4.3% | ||
| Q3 24 | -82.8% | -5.8% | ||
| Q2 24 | 15.9% | -7.9% | ||
| Q1 24 | 7.9% | -5.3% |
| Q4 25 | — | -6.6% | ||
| Q3 25 | 3.0% | -5.4% | ||
| Q2 25 | -2.7% | -7.7% | ||
| Q1 25 | 2.8% | -12.7% | ||
| Q4 24 | — | -10.7% | ||
| Q3 24 | -85.1% | -6.5% | ||
| Q2 24 | 10.6% | -8.5% | ||
| Q1 24 | 5.4% | -12.3% |
| Q4 25 | $0.05 | $-0.22 | ||
| Q3 25 | $0.12 | $-0.20 | ||
| Q2 25 | $-0.11 | $-0.23 | ||
| Q1 25 | $0.10 | $-0.29 | ||
| Q4 24 | $0.38 | $-0.26 | ||
| Q3 24 | $-3.11 | $-0.16 | ||
| Q2 24 | $0.39 | $-0.20 | ||
| Q1 24 | $0.19 | $-0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $238.4M | $49.9M |
| Total DebtLower is stronger | $372.2M | $444.1M |
| Stockholders' EquityBook value | $693.1M | $-1.9M |
| Total Assets | $1.3B | $1.2B |
| Debt / EquityLower = less leverage | 0.54× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $238.4M | $49.9M | ||
| Q3 25 | $246.3M | $34.0M | ||
| Q2 25 | $445.9M | $44.0M | ||
| Q1 25 | $493.6M | $33.1M | ||
| Q4 24 | $484.6M | $26.2M | ||
| Q3 24 | $453.8M | $22.4M | ||
| Q2 24 | $404.2M | $24.3M | ||
| Q1 24 | $325.9M | $12.6M |
| Q4 25 | $372.2M | $444.1M | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | $393.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $693.1M | $-1.9M | ||
| Q3 25 | $727.2M | $11.4M | ||
| Q2 25 | $757.8M | $18.2M | ||
| Q1 25 | $798.5M | $71.4M | ||
| Q4 24 | $778.3M | $97.5M | ||
| Q3 24 | $749.6M | $110.3M | ||
| Q2 24 | $879.3M | $81.5M | ||
| Q1 24 | $892.2M | $91.7M |
| Q4 25 | $1.3B | $1.2B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.5B | $1.2B | ||
| Q1 25 | $1.6B | $1.1B | ||
| Q4 24 | $1.6B | $1.1B | ||
| Q3 24 | $1.5B | $1.1B | ||
| Q2 24 | $1.6B | $1.1B | ||
| Q1 24 | $1.6B | $983.3M |
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | 4.03× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $43.7M | $36.7M |
| Free Cash FlowOCF − Capex | $43.5M | $27.8M |
| FCF MarginFCF / Revenue | 22.1% | 8.2% |
| Capex IntensityCapex / Revenue | 0.1% | 2.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $136.7M | $-107.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $43.7M | $36.7M | ||
| Q3 25 | $60.8M | $-26.6M | ||
| Q2 25 | $12.0M | $-7.0M | ||
| Q1 25 | $35.5M | $-22.1M | ||
| Q4 24 | $33.1M | $2.8M | ||
| Q3 24 | $53.9M | $-332.0K | ||
| Q2 24 | $53.2M | $-23.7M | ||
| Q1 24 | $49.1M | $8.0M |
| Q4 25 | $43.5M | $27.8M | ||
| Q3 25 | $57.0M | $-44.7M | ||
| Q2 25 | $9.3M | $-27.5M | ||
| Q1 25 | $26.9M | $-63.4M | ||
| Q4 24 | $31.0M | $-15.4M | ||
| Q3 24 | $49.8M | $-36.7M | ||
| Q2 24 | $51.6M | $-59.9M | ||
| Q1 24 | $46.3M | $-60.9M |
| Q4 25 | 22.1% | 8.2% | ||
| Q3 25 | 31.7% | -12.6% | ||
| Q2 25 | 5.1% | -9.8% | ||
| Q1 25 | 15.9% | -29.7% | ||
| Q4 24 | 16.6% | -6.7% | ||
| Q3 24 | 29.6% | -16.6% | ||
| Q2 24 | 29.0% | -28.7% | ||
| Q1 24 | 27.7% | -31.7% |
| Q4 25 | 0.1% | 2.6% | ||
| Q3 25 | 2.2% | 5.1% | ||
| Q2 25 | 1.5% | 7.3% | ||
| Q1 25 | 5.1% | 19.3% | ||
| Q4 24 | 1.1% | 7.9% | ||
| Q3 24 | 2.4% | 16.5% | ||
| Q2 24 | 0.9% | 17.4% | ||
| Q1 24 | 1.7% | 35.8% |
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | — | ||
| Q1 24 | 5.47× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
WEST
| Coffee And Tea | $202.6M | 60% |
| Flavors Extracts And Ingredients | $69.6M | 21% |
| Sustainable Sourcing And Traceability Segments | $66.9M | 20% |
